Correction to: British Journal of Cancer (2012) 107, 967–976. doi:10.1038/bjc.2012.356
Upon publication online and in print, the authors realised that a contributor to the original data for this manuscript had been omitted from the authorship of the final paper.
The authors and publishers are now happy to present the complete, full authorship above.
Change history
24 January 2013
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
Author information
Authors and Affiliations
Additional information
The online version of the original article can be found at 10.1038/bjc.2012.356
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Ryan, J., Tivnan, A., Fay, J. et al. Erratum: MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome. Br J Cancer 107, 1203 (2012). https://doi.org/10.1038/bjc.2012.425
Published:
Issue date:
DOI: https://doi.org/10.1038/bjc.2012.425
This article is cited by
-
miRNA-204 suppresses human non-small cell lung cancer by targeting ATF2
Tumor Biology (2016)
